Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 160

1.

A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence.

Johnson BA, Ait-Daoud N, Aubin HJ, Van Den Brink W, Guzzetta R, Loewy J, Silverman B, Ehrich E.

Alcohol Clin Exp Res. 2004 Sep;28(9):1356-61.

PMID:
15365306
[PubMed - indexed for MEDLINE]
2.

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.

Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW; Vivitrex Study Group.

JAMA. 2005 Apr 6;293(13):1617-25. Erratum in: JAMA. 2005 Jun 15:293(23):2864. JAMA. 2005 Apr 27;293(16):1978.

PMID:
15811981
[PubMed - indexed for MEDLINE]
3.

Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.

Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC.

Alcohol Clin Exp Res. 2006 Mar;30(3):480-90.

PMID:
16499489
[PubMed - indexed for MEDLINE]
4.

Extended-release intramuscular naltrexone.

Swainston Harrison T, Plosker GL, Keam SJ.

Drugs. 2006;66(13):1741-51. Review.

PMID:
16978037
[PubMed - indexed for MEDLINE]
5.

Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial.

Kranzler HR, Wesson DR, Billot L; DrugAbuse Sciences Naltrexone Depot Study Group.

Alcohol Clin Exp Res. 2004 Jul;28(7):1051-9.

PMID:
15252291
[PubMed - indexed for MEDLINE]
6.

Long-acting injectable naltrexone for the treatment of alcohol dependence.

Mannelli P, Peindl K, Masand PS, Patkar AA.

Expert Rev Neurother. 2007 Oct;7(10):1265-77. Review.

PMID:
17939765
[PubMed - indexed for MEDLINE]
7.

Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.

Galloway GP, Koch M, Cello R, Smith DE.

BMC Psychiatry. 2005 Apr 1;5:18.

PMID:
15804355
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Early treatment response in alcohol dependence with extended-release naltrexone.

Ciraulo DA, Dong Q, Silverman BL, Gastfriend DR, Pettinati HM.

J Clin Psychiatry. 2008 Feb;69(2):190-5.

PMID:
18348601
[PubMed - indexed for MEDLINE]
9.

Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics.

Lucey MR, Silverman BL, Illeperuma A, O'Brien CP.

Alcohol Clin Exp Res. 2008 Mar;32(3):498-504. doi: 10.1111/j.1530-0277.2007.00593.x. Epub 2008 Jan 30.

PMID:
18241321
[PubMed - indexed for MEDLINE]
10.

A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial.

Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramírez M, Mengual I, Gonzalvo B, Segura L, Trujols J, Casas M.

Alcohol Clin Exp Res. 2002 Sep;26(9):1381-7.

PMID:
12351933
[PubMed - indexed for MEDLINE]
11.

Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.

Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP.

Arch Gen Psychiatry. 2006 Feb;63(2):210-8.

PMID:
16461865
[PubMed - indexed for MEDLINE]
12.

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL.

Lancet. 2011 Apr 30;377(9776):1506-13. doi: 10.1016/S0140-6736(11)60358-9.

PMID:
21529928
[PubMed - indexed for MEDLINE]
13.

Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.

O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR.

J Clin Psychopharmacol. 2007 Oct;27(5):507-12.

PMID:
17873686
[PubMed - indexed for MEDLINE]
14.

The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence.

Dean RL.

Front Biosci. 2005 Jan 1;10:643-55. Review.

PMID:
15569605
[PubMed - indexed for MEDLINE]
15.

A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.

Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E.

Alcohol Clin Exp Res. 1994 Oct;18(5):1162-7.

PMID:
7847600
[PubMed - indexed for MEDLINE]
16.

Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: oral versus injectable delivery.

Roozen HG, de Waart R, van den Brink W.

Eur Addict Res. 2007;13(4):201-6.

PMID:
17851241
[PubMed - indexed for MEDLINE]
17.

Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.

Lobmaier PP, Kunøe N, Gossop M, Waal H.

CNS Neurosci Ther. 2011 Dec;17(6):629-36. doi: 10.1111/j.1755-5949.2010.00194.x. Review.

PMID:
21554565
[PubMed - indexed for MEDLINE]
19.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
[PubMed - indexed for MEDLINE]
20.

Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.

Hulse GK, Morris N, Arnold-Reed D, Tait RJ.

Arch Gen Psychiatry. 2009 Oct;66(10):1108-15. doi: 10.1001/archgenpsychiatry.2009.130.

PMID:
19805701
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk